



July 25, 2022

To,
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Stock Code: VAISHALI

SUB: OUTCOME OF THE MEETING OF THE BOARD OF DIRECTORS OF THE COMPANY HELD TODAY, JULY 25, 2022

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held today, has considered and approved the Un-audited Standalone Financial Results along with Limited Review Report for the quarter ended June 30, 2022, copy of the same is enclosed herewith.

Further, the Board Meeting commenced at 03:00 pm and concluded at 03:30 pm.

Kindly take the above on records.

Thanking you.

Yours faithfully,
For Vaishali Pharma Limited

Vishwa Mekhia
Company Secretary & Compliance Officer



Enclosed:-

- Un-Audited Standalone Financial Results for the Quarter Ended June 30, 2022;
- Limited Review Report issued by Chartered Accountant, M/s. Raman S. Shah & Associates, Chartered Accountants, for the Quarter Ended June 30, 2022.

RAMAN S. SHAH & ASSOCIATES
CHARTERED ACCOUNTANTS



CA Raman S. Shah, B.Com ,F.C.A.
CA Santosh A. Sankhe, B.Com ,F.C.A.
CA Bharat C. Bhandari, B.Com ,F.C.A.

Limited Review Report on Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
The Board of Directors of
Vaishali Pharma Limited

1. We have reviewed the quarterly financial results of **Vaishali Pharma Limited** for the quarter ended **June 30, 2022**, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our review of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.
2. We conducted our review in accordance with the Standards on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Internal Auditor of the Entity" issued by the Institute of Chartered of India (ICAI). Those standards require that we plan and perform the review to obtain reasonable assurance about whether the financial results are free of material misstatement. A review includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. A review also includes assessing the accounting principles used and significant estimates made by management. We believe that our review provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us, the standalone financial results:
 - i. Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circulars CIR/CFD/CMD [11] 2011 dated 30th November 2015 and CIR/CFD/FAC [62] 2016 dated 5th July, 2016 in this regard; and
 - ii. Gives a true and fair view of the standalone net profit and other financial information in conformity with the accounting principles generally accepted in India, including Accounting Standards, specified under Section 133 of the Act for the Quarter ended June 30, 2022.

For Raman S. Shah & Associates
Chartered Accountants

Firm Registration No. 119891W


Santosh A. Sankhe

Partner

Membership No. 100976

Place:- Mumbai

Date:- 25/07/2022



UDIN-22100976ANOLPY6223

Head Office:- SamPlaza, 'A' Wing, 2nd Floor, H.K.Irani Road, Dahanu Road (W) 401602

Branch Office:- I) A-104, 1st Floor, InderDarshan Building, Jamli Gali, Borivali (W), Mumbai (W), 400092

2) 118, 124, 1st Floor, "Harmony Plaza" Taranur Road, Boisar, 401501

Vaishali Pharma Ltd.



CORPORATE & REGISTERED OFFICE :
706-709, 7th Floor, Aravali Business Cent
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : cs@vaishalipharma.com
investor@vaishalipharma.com
CIN - L52310MH2008PLC181632



Statement of unaudited financial results for the quarter ended June 30, 2022

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended	Quarter Ended	Quarter Ended	Year Ended
		30-Jun-22 (Unaudited)	31-Mar-22 (Unaudited)	30-Jun-21 (Unaudited)	31-Mar-22 (Audited)
1	Revenue from operations				
	a) Sales/Income from operations	966.44	2,155.75	813.85	7,153.68
	b) Other operating income	51.56	385.04	13.14	428.40
	Total Revenue from operations	1,018.00	2,540.79	826.99	7,582.08
2	Other income	43.43	55.14	56.67	178.81
3	Total Income (1+2)	1,061.43	2,595.93	883.66	7,760.89
4	Expenditure				
	a) Cost of Material Consumed	-	-	-	-
	a) Purchase of Stock-in-trade	630.91	2,228.86	629.33	6,354.13
	b) Changes in Inventories of Finished Goods, Work-in-progress and Stock-in-trade	23.34	87.36	(1.10)	(4.07)
	c) Employee benefit expenses	50.49	59.85	41.93	209.92
	d) Finance cost	52.94	64.81	65.20	245.88
	e) Depreciation and amortisation expenses	8.83	14.99	10.19	45.63
	f) Other expenses	93.42	76.66	29.86	336.57
	Total Expenses (a to f)	859.93	2,532.53	775.41	7,188.06
5	Profit before Exceptional Items and Tax	201.50	63.40	108.25	572.83
6	Exceptional items debit / (credit)	-	-	-	-
7	Profit before Tax	201.50	63.40	108.25	572.83
8	Tax Expenses				
	Current Tax (Net) Debit / (Credit)	50.37	18.13	27.06	145.48
	Tax for earlier year	-	26.81	-	26.81
	Deferred Tax (Net) Debit / (Credit)	-	(1.82)	-	(1.82)
	Total Tax Expenses	50.37	43.12	27.06	170.47
9	Net Profit for the period	151.12	20.28	81.19	402.36
10	Other Comprehensive Income				
	a) Items that will not be reclassified to profit and loss (Net of Tax)				
	- Remeasurements of the defined benefit plans : (Losses)/ Gains	-	1.65	-	1.65
	b) Items that will be reclassified to profit and loss	-	-	-	-
11	Total comprehensive income for the period	151.12	21.93	81.19	404.01
12	Paid up Equity Share Capital (Face Value of Rs. 10/-)	1,054.62	1,054.62	1,054.62	1,054.62
13	Other equity				1,580.80
14	Earning Per Share (For continuing operations based on Weighted Average) -In INR (Not Annualised)				
	Basic	1.43	0.19	0.77	3.82
	Diluted	1.43	0.19	0.77	3.82

For and on behalf of Board

Mumbai
July 25, 2022



[Signature]
Director



Vaishali Pharma Ltd.



CORPORATE & REGISTERED OFFICE
706-709, 7th Floor, Aravali Business Center,
R. C. Patel Road, Off. Sodawala Lane,
Borivali (West), Mumbai-400 092.
Tel.: +91-22-4217 1819
E-mail : cs@vaishalipharma.com
investor@vaishalipharma.com
CIN - L52310MH2008PLC181632

1. The above financial results for the quarter ended 30th June, 2022 were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 25th July, 2022.
2. The above Unaudited Financial results is subject to Limited Review Report as furnished by the Statutory Auditors and approved by the Board of Directors of the Company as received under regulation 33 of SEBI (LODR) Regulation 2015.
3. Figures of previous reporting periods have been regrouped / reclassified wherever necessary to correspond with the figures of the current reporting period.
4. The Company has one segment of activity viz., Sale of pharmaceutical products.

By the order of the Board
For Vaishali Pharma Limited

Alankar D. S.
Director



Place : Mumbai
Date : July 25, 2022

